Synthetic analog · 3 amino acids · 390.4 Da

Vesugen (KED) studies and research data

PepBank has 13 Vesugen studies with results. 10 of them gave Vesugen, with 23 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.

Searches 23 results and 23 papers. Newer studies from Europe PMC

Results in people

22% of 23 results

Results in animals

0% of 23 results

Results in lab cells

78% of 23 results

From computer models

0% of 23 results

The molecule

Vesugen identity

Identifiers, parent molecule, targets and development stage, from curated data.

Vesugen is a synthetic 3-residue peptide in the Khavinson bioregulator family. Its sequence is Lys-Glu-Asp. Chemical identity does not establish a clinical benefit or a safe human dose.

Kind: Synthetic analog · 3 residues
Identifiers: PubChem CID87571363 (opens in a new tab)CAS204271-66-9
Development: No known clinical developmentNo clinical development phase was established from the identity and regulatory sources. Study titles do not establish a clinical phase.

Targets

No molecular target is recorded for this peptide.

Sequence and structure

Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.

Sequence

3 amino acids

H-

KED

-OH

Properties

From identity sources

Formula: C₁₅H₂₆N₄O₈
Molecular weight: 390.39 g/mol
Monoisotopic mass: 390.1751 Da

PubChem CID 87571363(opens in a new tab)retrieved 2026-10-21
Curated Supplier identity statement(opens in a new tab)retrieved 2026-10-21

Calculated from the sequence

pKa set

Average mass: 390.39 Da; Sum of ExPASy residue masses + water · ExPASy Compute pI/Mw; FindMod
Monoisotopic mass: 390.1751 Da; Sum of ExPASy residue masses + water · ExPASy FindMod
Isoelectric point (pI): 4.18; pH of zero net charge, EMBOSS pKa set · EMBOSS iep, Epk.dat
Net charge at pH 7.4: −1.06; Henderson-Hasselbalch, EMBOSS pKa set · EMBOSS iep, Epk.dat
GRAVY (hydropathy): −3.633; Mean Kyte-Doolittle hydropathy · Kyte and Doolittle 1982; Negative: hydrophilic on average.
Extinction coefficient, 280 nm (Cys reduced): 0 M⁻¹ cm⁻¹; 5500 x Trp + 1490 x Tyr · Pace et al. 1995 (ExPASy ProtParam); No Trp or Tyr: absorbance at 280 nm cannot measure this peptide.
Instability index: 70.87; Dipeptide instability weights (DIWV) · Guruprasad et al. 1990; Above 40: classed as possibly unstable (ExPASy).
Aliphatic index: 0.0; Mole % A + 2.9 V + 3.9 (I + L) · Ikai 1980
Boman index: 7.03 kcal/mol; Mean solubility value (negated) · Boman 2003; Above 2.48: high protein-binding potential (Boman).
Hydrophobic moment (μH): Not calculated; The sequence is too short for this method.
pI with each pKa set: EMBOSS 4.18Bjellqvist (ExPASy) 4.67IPC peptide 4.12IPC protein 4.19

Defined and validated for proteins; use with care for short peptides.
Assumes an ideal alpha helix. Many short peptides are not helical.

@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses

Net charge by pH

pI 4.18 · Net charge at pH 7.4: −1.06

Point or use arrow keys

Henderson-Hasselbalch, EMBOSS pKa set. Calculated, not measured.

Show as table

pH	Net charge
0	2.00
1	2.00
2	1.96
3	1.61
4	0.28
5	−0.78
6	−0.98
7	−1.02
8	−1.20
9	−1.73
10	−2.10
11	−2.61
12	−2.94
13	−2.99
14	−3.00

Composition

Positive33% (1)K
Negative67% (2)D E

3 residues. Each residue counts in one class; F and W count as aromatic.

A Ala0 · 0%

I Ile0 · 0%

L Leu0 · 0%

M Met0 · 0%

V Val0 · 0%

F Phe0 · 0%

W Trp0 · 0%

Y Tyr0 · 0%

H His0 · 0%

K Lys1 · 33%

R Arg0 · 0%

D Asp1 · 33%

E Glu1 · 33%

N Asn0 · 0%

Q Gln0 · 0%

S Ser0 · 0%

T Thr0 · 0%

C Cys0 · 0%

G Gly0 · 0%

P Pro0 · 0%

3D structure

No 3D structure

No experimental structure (PDB) and no UniProt entry for an AlphaFold model are listed for this peptide. Synthetic peptides often have neither. The sequence view above is the reference.

2D structure

Draws the structure in your browser with RDKit (about 2.3 MB, loaded once).

SMILES fromPubChem CID 87571363(opens in a new tab)

C(CCN)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N

Results by area

Vesugen results by year and outcome

Counts are exact and come from studies that gave the peptide.

Studies by year

13 of 23 studies have results (57%), published 2011 to 2020. Top row: every study. Bottom row: studies with results about Vesugen (KED), by class. The rows use different scales.

Studies
Human
Animal
Lab
Computer model
Natural levels, tool or combination only

Studies23 in all, 2008 to 2022

Studies with results13 in all, 2011 to 2020

Retracted studies are left out. A study with results in two classes counts in both.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

What the studies measured

People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.

Vesugen studies on cells, genes and aging

11 results · people 2 · animals 0 · lab 9

Top 5 of 11 results

In these patients, Vesugen showed a greater reported effect against aging than Pinealon.Advances in gerontology = Uspekhi gerontologii, 2015
In patients with several diseases and organic brain syndrome in remission, Vesugen increased anabolic activity.Advances in gerontology = Uspekhi gerontologii, 2015
In cells, vesugen increased proliferation-associated Ki-67 protein.Advances in gerontology = Uspekhi gerontologii, 2014
In cells, KED reduced p16 gene expression compared with control.Stem cell reviews and reports, 2020
In cells, KED reduced FOXO1 expression by 1.6-2.3 fold.Molecular biology reports, 2020

Vesugen studies on heart and blood vessels

1 result · people 1 · animals 0 · lab 0

1 result

In patients after surgery for leg ischemia, Vezugen improved leg blood flow on clinical and ultrasound measures compared with before treatment.Advances in gerontology = Uspekhi gerontologii, 2013

Vesugen studies on sexual and women's health

1 result · people 1 · animals 0 · lab 0

1 result

In patients with vascular erectile dysfunction, Vezugen improved penile arterial blood flow compared with before treatment.Advances in gerontology = Uspekhi gerontologii, 2014

Vesugen studies on side effects

1 result · people 1 · animals 0 · lab 0

1 result

In patients with several diseases and organic brain syndrome in remission, Vesugen did not change chromatin condensation.Advances in gerontology = Uspekhi gerontologii, 2015

Vesugen studies on receptors and cell signals

7 results · people 0 · animals 0 · lab 7

Top 5 of 7 results

In cells, KED normalized the high endothelin-1 expression associated with atherosclerosis and restenosis.Advances in gerontology = Uspekhi gerontologii, 2016
In human prostate cells, vesugen increased CXCL12 expression.Bulletin of experimental biology and medicine, 2012
In cells, KED alone increased GAP43 expression.International journal of immunopathology and pharmacology, 2019
In cells, KED restored cell interactions through connexin expression.Advances in gerontology = Uspekhi gerontologii, 2016
In human prostate cells, vesugen increased WEGC1 expression.Bulletin of experimental biology and medicine, 2012

Vesugen studies on immune system and inflammation

2 results · people 0 · animals 0 · lab 2

2 results

In lab tests, vesugen did not change the ability of pineal immune cells to differentiate.Bulletin of experimental biology and medicine, 2011
In lab tests, vesugen increased the ability of pineal immune cells to multiply.Bulletin of experimental biology and medicine, 2011

Trials and papers

Vesugen trials

Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.

StatusPhase

0 trials match. Highest phase first. Data from ClinicalTrials.gov.

No trial matches these filters.

Papers

Studies on this peptide. Some have results. The others have none yet.

Sort

Design

23 studies match. Retracted studies are left out.

Showing 17 of 23 studiesquery qry_fdd0efb34543d718d4aeffb7

Studies with results

13 studies

In vitro (cells) · 2019

6 results

Effect of short peptides on neuronal differentiation of stem cells.

Caputi et al. 2019International journal of immunopathology and pharmacologycited by 43

PMID 30791821PMC6376556DOI 10.1177/2058738419828613PUB-30791821

Free to read · publisher termsCC BY-NC2 results where Vesugen (KED) was given (plus 2 on tools or combinations, listed separately)

Read at source See results (6)

In vitro (cells) · 2020

6 results

Short Peptides Protect Oral Stem Cells from Ageing.

Sinjari et al. 2020Stem cell reviews and reportscited by 18

PMID 31677028DOI 10.1007/s12015-019-09921-3PUB-31677028

Full text at the publisher4 results where Vesugen (KED) was given

Publisher page See results (6)

In vitro (cells) · 2020

4 results

Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides.

Ashapkin et al. 2020Molecular biology reportscited by 10

PMID 32399807DOI 10.1007/s11033-020-05506-3PUB-32399807

Full text at the publisher4 results where Vesugen (KED) was given

Publisher page See results (4)

In vitro (cells) · 2012

6 results

Peptides tissue-specifically stimulate cell differentiation during their aging.

VKh et al. 2012Bulletin of experimental biology and medicinecited by 6

PMID 22808515DOI 10.1007/s10517-012-1664-1PUB-22808515

Full text at the publisher2 results where Vesugen (KED) was given

Publisher page See results (6)

In vitro (cells) · 2014

2 results

[Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging].

VKh et al. 2014Advances in gerontology = Uspekhi gerontologiicited by 4

PMID 25051766DOI 10.1134/s2079057015040116PUB-25051766

Full text at the publisher1 result where Vesugen (KED) was given (plus 1 on tools or combinations, listed separately)

Publisher page See results (2)

In vitro (cells) · 2016

3 results

[Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis].

Kozlov et al. 2016Advances in gerontology = Uspekhi gerontologiicited by 4

PMID 28539025PUB-28539025

Full text at the publisher3 results where Vesugen (KED) was given

Publisher page See results (3)

Not a test of Vesugen (KED) alone · 2012

5 results

[The peptide correction of neurotic disorders among professional truck-drivers].

Bashkireva et al. 2012Advances in gerontology = Uspekhi gerontologiicited by 3

PMID 23734521PUB-23734521

Full text at the publisher1 result where Vesugen (KED) was a tool, carrier or part of a combination

Publisher page See results (5)

Ex vivo tissue · 2011

6 results

Peptidegic stimulation of differentiation of pineal immune cells.

Linkova et al. 2011Bulletin of experimental biology and medicinecited by 2

PMID 22803057DOI 10.1007/s10517-011-1470-1PUB-22803057

Full text at the publisher2 results where Vesugen (KED) was given

Publisher page See results (6)

Non-randomized trial · 2014

1 result

[The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people].

Kitachev et al. 2014Advances in gerontology = Uspekhi gerontologiin = 41cited by 2

PMID 25051774PUB-25051774

Full text at the publisher1 result where Vesugen (KED) was given

Publisher page See results (1)

Non-randomized trial · 2015

10 results

[EFFECT OF SYNTHETIC PEPTIDES ON AGING OF PATIENTS WITH CHRONIC POLYMORBIDITY AND ORGANIC BRAIN SYNDROME OF THE CENTRAL NERVOUS SYSTEM IN REMISSION].

Meshchaninov et al. 2015Advances in gerontology = Uspekhi gerontologiicited by 1

PMID 26390612PUB-26390612

Full text at the publisher3 results where Vesugen (KED) was given

Publisher page See results (10)

Non-randomized trial · 2013

1 result

[The role of vasoactive peptid in lower limbs chronic arterial insufficiency treatment].

Kitachov et al. 2013Advances in gerontology = Uspekhi gerontologiin = 41cited by 1

PMID 28976154PUB-28976154

Full text at the publisher1 result where Vesugen (KED) was given

Publisher page See results (1)

Not a test of Vesugen (KED) alone · 2016

3 results

[Comparative analysis of different methods of geroprotective].

Myakotnykh et al. 2016Advances in gerontology = Uspekhi gerontologii

PMID 28539017PUB-28539017

Full text at the publisher1 result where Vesugen (KED) was a tool, carrier or part of a combination

Publisher page See results (3)

Not a test of Vesugen (KED) alone · 2013

1 result

[TREATMENT OF CHEMICAL STOMATITIS IN PEOPLE OF ADVANCED AND SENILE AGE].

Filippova et al. 2013Advances in gerontology = Uspekhi gerontologii

PMID 28976153PUB-28976153

Full text at the publisher1 result where Vesugen (KED) was a tool, carrier or part of a combination

Publisher page See results (1)

More studies

4 studies

PubMed tag: review-article, Review · 2022

Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation.

Khavinson et al. 2022Cellscited by 47

PMID 36611900PMC9818427DOI 10.3390/cells12010106PUB-36611900

CC BY

Download PDF

PubMed tag: none · 2021

Corrected

Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer's Disease.

Khavinson et al. 2021Pharmaceuticals (Basel, Switzerland)cited by 13

PMID 34071923PMC8227791DOI 10.3390/ph14060515PUB-34071923

CC BY

Download PDF Read the notice

Indexing hint: Animal study · 2017

Corrected

Tripeptides Restore the Number of Neuronal Spines under Conditions of In Vitro Modeled Alzheimer's Disease.

Kraskovskaya et al. 2017Bulletin of experimental biology and medicinecited by 12

PMID 28853087DOI 10.1007/s10517-017-3847-2PUB-28853087

Full text at the publisher

Publisher page Read the notice

PubMed tag: Review · 2021

Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease.

Khavinson et al. 2021Bulletin of experimental biology and medicinecited by 7

PMID 34173097DOI 10.1007/s10517-021-05192-6PUB-34173097

Full text at the publisher

Publisher page

No result for Vesugen (KED) (6 studies on this page)

These studies name Vesugen (KED) but give no result for it (for example, the results concern another peptide in the study).

PubMed tag: Review · 2020

Peptide Regulation of Cell Differentiation.

Khavinson et al. 2020Stem cell reviews and reportscited by 18

PMID 31808038DOI 10.1007/s12015-019-09938-8PUB-31808038

Full text at the publisher

Publisher page

Indexing hint: Animal study · 2016

Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro.

Lin'kova et al. 2016Bulletin of experimental biology and medicinecited by 14

PMID 27259496DOI 10.1007/s10517-016-3370-xPUB-27259496

Full text at the publisher

Publisher page

Indexing hint: In vitro study · 2008

10 results

[Biological activity of regulatory peptides in model experiments in vitro].

Kozina et al. 2008Advances in gerontology = Uspekhi gerontologiicited by 2

PMID 18546826PUB-18546826

Full text at the publisher10 results

Publisher page See results (10)

PubMed tag: none · 2020

[Short peptides: regulation of skin function during aging.]

Khavinson et al. 2020Advances in gerontology = Uspekhi gerontologiicited by 1

PMID 32362083PUB-32362083

Full text at the publisher

Publisher page

Indexing hint: Animal study · 2008

6 results

[Investigation of antihypoxic properties of short peptides].

Kozina et al. 2008Advances in gerontology = Uspekhi gerontologii

PMID 18546825PUB-18546825

Full text at the publisher6 results

Publisher page See results (6)

PubMed tag: none · 2021

[Epigenetic regulation of adaptogenesis by pathology and aging.]

Rubinskii et al. 2021Advances in gerontology = Uspekhi gerontologii

PMID 33993656DOI 10.34922/ae.2021.34.1.001PUB-33993656

Full text at the publisher

Publisher page

Newer studies

PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.

Vesugen (KED) studies: 13 papers with results

Page 1 of 1

[The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people].
Kitachev KV · Advances in gerontology = Uspekhi gerontologii · 2014
Non-randomized trial · 1 result
[The role of vasoactive peptid in lower limbs chronic arterial insufficiency treatment].
Kitachov KV · Advances in gerontology = Uspekhi gerontologii · 2013
Non-randomized trial · 1 result
[EFFECT OF SYNTHETIC PEPTIDES ON AGING OF PATIENTS WITH CHRONIC POLYMORBIDITY AND ORGANIC BRAIN SYNDROME OF THE CENTRAL NERVOUS SYSTEM IN REMISSION].
Meshchaninov VN · Advances in gerontology = Uspekhi gerontologii · 2015
Non-randomized trial · 10 results
Peptidegic stimulation of differentiation of pineal immune cells.
Linkova NS · Bulletin of experimental biology and medicine · 2011
Ex vivo tissue · 6 results
Effect of short peptides on neuronal differentiation of stem cells.
Caputi S · International journal of immunopathology and pharmacology · 2019
In vitro (cells) · 6 results
Short Peptides Protect Oral Stem Cells from Ageing.
Sinjari B · Stem cell reviews and reports · 2020
In vitro (cells) · 6 results
Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides.
Ashapkin V · Molecular biology reports · 2020
In vitro (cells) · 4 results
Peptides tissue-specifically stimulate cell differentiation during their aging.
Khavinson VKh · Bulletin of experimental biology and medicine · 2012
In vitro (cells) · 6 results
[Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis].
Kozlov KL · Advances in gerontology = Uspekhi gerontologii · 2016
In vitro (cells) · 3 results
[Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging].
Khavinson VKh · Advances in gerontology = Uspekhi gerontologii · 2014
In vitro (cells) · 2 results
[The peptide correction of neurotic disorders among professional truck-drivers].
Bashkireva AS · Advances in gerontology = Uspekhi gerontologii · 2012
Not a test of Vesugen (KED) alone · 5 results
[Comparative analysis of different methods of geroprotective].
Myakotnykh VS · Advances in gerontology = Uspekhi gerontologii · 2016
Not a test of Vesugen (KED) alone · 3 results
[TREATMENT OF CHEMICAL STOMATITIS IN PEOPLE OF ADVANCED AND SENILE AGE].
Filippova EV · Advances in gerontology = Uspekhi gerontologii · 2013
Not a test of Vesugen (KED) alone · 1 result

Status and safety

Regulatory and safety

Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.

Regulatory status by jurisdiction, with date and source
Jurisdiction	Body	Status	As of	Source
US	FDA	The cited Drugs@FDA search returned NOT_FOUND for Vesugen, Vezugen and Lys-Glu-Asp. This limited search found no approval. It does not establish absence under all chemical names or identifiers. Compounding status remains unresolved.	22 Oct 2026	api.fda.gov (opens in a new tab)
EU	EMA	The EMA data contained 2,754 records dated 2026-10-21. No Vesugen, Vezugen or Lys-Glu-Asp match appeared. This central dataset does not establish EU national approval status. Overall EU approval status remains unresolved.	22 Oct 2026	ema.europa.eu (opens in a new tab)
Sport	WADA	Status unknown The peptide is not named in the 2026 list.	2026 List	wada-ama.org (opens in a new tab)
Russia	Note	Registered in Russia as a dietary supplement, not as a medicine. It is not approved as a medicine. Current supplement certificate RU.77.99.88.003.R.002043.08.25 of 2025-08-07 (earlier 77.99.23.3.U.9172.8.06), read from a copy of the supplement register (reestrinform.ru, accessed 2026-10-22). The manufacturer also lists it as a dietary supplement. No entry in the State Register of Medicines was found.	22 Oct 2026	reestrinform.ru (opens in a new tab)

Safety outcomes

1 safety result for Vesugen (KED).

Human evidence· 1

In patients with polymorbidity and organic brain syndrome in remission, Vesugen and Pinealon did not affect chromatin condensation.
Non-randomized trialn not reported

Doses studied

The doses that these studies used. They are not recommendations.

No dose was reported in the study results.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Data

Data and API

Data version, change history and code for this peptide.

Data version 30856030 Oct 2026

Peptide

Peptide id: PEP-000100
Peptide version: 4
Peptide hash: b830d94b2bbe543b…
Data version: 308560

Latest changes

27 Oct 2026UpdatedData version 256797
22 Oct 2026UpdatedData version 254591
21 Oct 2026UpdatedData version 228029
21 Oct 2026CreatedData version 226698

For developers

curl -s https://pepbank.io/v1/briefs/vesugen

Evidence summary for Vesugen (KED): counts by class, key results with sources, notices, data version.

Peptide as JSON Evidence summary as JSON

Outcome group	Human	Animal	Lab	Computer model	Total
Aging markersWhole body	Human: 2 results from 1 study: 2 increase. Strongest design: Non-randomized trial	No results	Lab: 9 results from 3 studies: 3 increase, 6 decrease. Strongest design: In vitro (cells)	No results	11
Adverse eventsWhole body	Human: 1 result from 1 study: 1 no significant change. Strongest design: Non-randomized trial	No results	No results	No results	1
Sexual functionReproductive and sexual health	Human: 1 result from 1 study: 1 increase. Strongest design: Non-randomized trial	No results	No results	No results	1
Vascular functionCardiovascular	Human: 1 result from 1 study: 1 increase. Strongest design: Non-randomized trial	No results	No results	No results	1
Receptor activity and mechanismNervous system and cognition	No results	No results	Lab: 7 results from 3 studies: 5 increase, 1 decrease, 1 not reported. Strongest design: In vitro (cells)	No results	7
Immune responseImmune and inflammation	No results	No results	Lab: 2 results from 1 study: 1 increase, 1 no significant change. Strongest design: Ex vivo tissue	No results	2

Outcome group	Human	Animal	Lab	Computer model	Total
Aging markersWhole body	Human: 2 results from 1 study: 2 increase. Strongest design: Non-randomized trial	No results	Lab: 9 results from 3 studies: 3 increase, 6 decrease. Strongest design: In vitro (cells)	No results	11
Adverse eventsWhole body	Human: 1 result from 1 study: 1 no significant change. Strongest design: Non-randomized trial	No results	No results	No results	1
Sexual functionReproductive and sexual health	Human: 1 result from 1 study: 1 increase. Strongest design: Non-randomized trial	No results	No results	No results	1
Vascular functionCardiovascular	Human: 1 result from 1 study: 1 increase. Strongest design: Non-randomized trial	No results	No results	No results	1
Receptor activity and mechanismNervous system and cognition	No results	No results	Lab: 7 results from 3 studies: 5 increase, 1 decrease, 1 not reported. Strongest design: In vitro (cells)	No results	7
Immune responseImmune and inflammation	No results	No results	Lab: 2 results from 1 study: 1 increase, 1 no significant change. Strongest design: Ex vivo tissue	No results	2

Vesugen (KED) studies and research data

Vesugen identity

Targets

Sequence and structure

Sequence

Properties

Net charge by pH

Composition

3D structure

2D structure

Vesugen results by year and outcome

What the studies measured

Vesugen studies on cells, genes and aging

Vesugen studies on heart and blood vessels

Vesugen studies on sexual and women's health

Vesugen studies on side effects

Vesugen studies on receptors and cell signals

Vesugen studies on immune system and inflammation

Vesugen trials

Papers

Studies with results

Effect of short peptides on neuronal differentiation of stem cells.

Short Peptides Protect Oral Stem Cells from Ageing.

Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides.

Peptides tissue-specifically stimulate cell differentiation during their aging.

[Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging].

[Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis].

[The peptide correction of neurotic disorders among professional truck-drivers].

Peptidegic stimulation of differentiation of pineal immune cells.

[The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people].

[EFFECT OF SYNTHETIC PEPTIDES ON AGING OF PATIENTS WITH CHRONIC POLYMORBIDITY AND ORGANIC BRAIN SYNDROME OF THE CENTRAL NERVOUS SYSTEM IN REMISSION].

[The role of vasoactive peptid in lower limbs chronic arterial insufficiency treatment].

[Comparative analysis of different methods of geroprotective].

[TREATMENT OF CHEMICAL STOMATITIS IN PEOPLE OF ADVANCED AND SENILE AGE].

More studies

Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation.

Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer's Disease.

Tripeptides Restore the Number of Neuronal Spines under Conditions of In Vitro Modeled Alzheimer's Disease.

Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease.

Peptide Regulation of Cell Differentiation.

Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro.

[Biological activity of regulatory peptides in model experiments in vitro].

[Short peptides: regulation of skin function during aging.]

[Investigation of antihypoxic properties of short peptides].

[Epigenetic regulation of adaptogenesis by pathology and aging.]

Newer studies

Vesugen (KED) studies: 13 papers with results

Regulatory and safety

Human evidence· 1

Doses studied

Data and API

Peptide

Latest changes

For developers

Related peptides

Vesugen results by year and outcome

Vesugen studies on cells, genes and aging

Vesugen studies on heart and blood vessels

Vesugen studies on sexual and women's health

Vesugen studies on side effects

Vesugen studies on receptors and cell signals

Vesugen studies on immune system and inflammation

Vesugen trials

Papers

Studies with results

Effect of short peptides on neuronal differentiation of stem cells.

Short Peptides Protect Oral Stem Cells from Ageing.

Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides.

Peptides tissue-specifically stimulate cell differentiation during their aging.

[Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging].

[Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis].

[The peptide correction of neurotic disorders among professional truck-drivers].

Peptidegic stimulation of differentiation of pineal immune cells.

[The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people].

[EFFECT OF SYNTHETIC PEPTIDES ON AGING OF PATIENTS WITH CHRONIC POLYMORBIDITY AND ORGANIC BRAIN SYNDROME OF THE CENTRAL NERVOUS SYSTEM IN REMISSION].

[The role of vasoactive peptid in lower limbs chronic arterial insufficiency treatment].

[Comparative analysis of different methods of geroprotective].

[TREATMENT OF CHEMICAL STOMATITIS IN PEOPLE OF ADVANCED AND SENILE AGE].

More studies

Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation.